Drug Injury Watch

Side Effects News & Reports

From 2005 to the Present

All Articles by Tom Lamb

Tag: FDA warnings

Xeljanz: FDA Warnings Updated: There are Higher Rates of Blood Clots and Deaths for Both Doses of Xeljanz, Now

September 1, 2021

JAK Inhibitors Xeljanz, Olumiant, and Rinvoq Get Drug Label Changes and Drug Use Limitations in September 2021 (Posted by Tom Lamb at Drug Injury Watch) On September 1, 2021, the FDA released this alerting news…
Continue reading…
Zantac Recall In April 2020 Comes 7 Months After The Zantac FDA Warning In September 2019

May 27, 2020

Level Of Chemical NDMA In Zantac Pills Can Cause Cancers: Pancreatic, Stomach, Colon, Rectal, Bladder, Kidney (Posted by Tom Lamb at DrugInjuryWatch.com) On April 1, 2020, the FDA announced that it was…
Continue reading…
Are Zantac NDMA Levels Increased By Heat Exposures During Shipping And Storage?

January 3, 2020

This Theory Would Explain Why NDMA Was Not Found To Be A Problem At Zantac Manufacturing Sites (Posted by Tom Lamb at DrugInjuryWatch.com) The fact that Zantac contains NDMA (nitrosamine impurity called…
Continue reading…
Zantac FDA Warning In September 2019 Leads To Lawsuits For Patients Diagnosed With Cancer

November 29, 2019

Cases Involve Stomach, Colon, Rectal, Bladder, Kidney, And Pancreatic Cancers Diagnosed After Taking Zantac (Posted by Tom Lamb at DrugInjuryWatch.com) Zantac cancer lawsuits are being filed for patients diagnosed with certain types…
Continue reading…
Uloric “Black-Box Warning” For Increased Risks Of Heart-Related Deaths And Cardiovascular Side Effects

March 4, 2019

February 2019: Despite Safety Trial Finding A Link To Cardiac Deaths, FDA Does Not Order Uloric Recall At This Time (Posted by Tom Lamb at DrugInjuryWatch.com) This new article about the gout…
Continue reading…
Gadolinium Retention Warnings Added To Drug Labels For Gadolinium Contrast Agents Used During MRI / MRA

May 17, 2018

Label Changes Announced By FDA In December 2017 Finally Approved For Magnevist, Omniscan, And Other GBCAs In April 2018 (Posted by Tom Lamb at DrugInjuryWatch.com) Gadolinium based contrast agents (GBCAs) are substances…
Continue reading…
Invokana, Invokamet, Farxiga, Xigduo: Warnings About Acute Kidney Injury Risk Are Increased On Revised Drug Labels For These Diabetes Medicines

June 22, 2016

Meanwhile Jardiance, Glyxambi, And Synjardy, Also In The SGLT2 Inhibitors Class Of Diabetes Drugs, May Help Slow Progression Of Kidney Disease In Patients At High Cardiovascular Risk (Posted by Tom Lamb at DrugInjuryWatch.com)…
Continue reading…
Zecuity Recall: Teva Migraine Drug Patch Gets FDA Warning About Reports Of Serious Burns And Potential Permanent Scarring

June 13, 2016

Drug Company Announces It Will Recall Zecuity Skin Patches From Pharmacies As Well As Temporarily Suspend Sales, Marketing, And Distribution Of Product (Posted by Tom Lamb at DrugInjuryWatch.com) UPDATE: Zecuity Migraine…
Continue reading…
Diabetes Drug Invokana Gets Label Changes For New Warnings About Increased Risk Of Bone Fracture Risks

September 25, 2015

The FDA Is Investigating Whether Farxiga And Jardiance Are Also Associated With Higher Rates Of Bone Breaks (Posted by Tom Lamb at DrugInjuryWatch.com) ________________________________________________________________________________ UPDATE: “Health Canada Warns About Link Between DKA &…
Continue reading…
Potential Link Between MS Drug Gilenya And Cancers, Neoplasms, Or Tumors According To Health Canada

September 15, 2015

This September 2015 Drug Safety Alert Is Based Primarily On Reports Of Skin Cancer And Lymphoma Blood Cancer (Posted by Tom Lamb at DrugInjuryWatch.com) Health Canada recently conducted a review of safety…
Continue reading…